Michael Kaseta is recorded as COO at Liquidia Corp (LQDA) since January 15, 2024 and CFO at Liquidia Corp (LQDA). The newest filing on record that lists Michael Kaseta as CFO at Liquidia Corp (LQDA) is dated April 24, 2026. Liquidia Corp reported in an 8-K filed January 19, 2024 that Michael Kaseta was appointed Chief Operating Officer, effective January 15, 2024. The proxy statement of Liquidia Corp reports total compensation of $4,156,063 for Michael Kaseta in fiscal 2025, including a base salary of $592,250. Disclosed compensation is on record for 5 fiscal years. Michael Kaseta has spoken on 11 earnings calls and 1 other investor event across 1 company, most recently for Liquidia Corp on August 12, 2026. Liquidia Corp is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Liquidia Corp includes Damian deGoa (CEO and Board Member), Joanna Horobin (CEO), Paul B. Manning (CEO and Board Member) and 7 others.
“On January 15, 2024 (the “Effective Date”), the Company promoted Michael Kaseta, the current Chief Financial Officer (“CFO”) of the Company, to the role of Chief Operating Officer (the “COO”), effective immediately.”
Liquidia Corp Form 8-K, filed January 19, 2024
· Read the filing
Michael Kaseta on recent calls
“I'm pleased to say the second quarter of financial performance continued to reflect the growth trajectory for Eutrepia we've described to date.”
“You know, since launch, our goal was always to make sure the patients had a choice if they wanted to choose Eutrepia, and we've achieved that goal here in the early part of launch where, you know, for the vast majority, we are at parity.”
“Our financial results are a direct reflection of two things, sustained patient growth and retention, and disciplined execution. Over the last nine months, as the referral and start curves have moved higher, so have revenue, margin contribution, and cash generation.”
“The third quarter of 2025 was truly a breakthrough quarter for Liquidia, both operationally and financially. During the quarter, our first full quarter of launch, we delivered $51.7 million in net product sales of YUTREPIA.”
“In order to save time for more of your questions, I'd just like to hit the headlines on the financial statements filed this morning with the SEC and in our press release.”
